While EGFR mutations drive tumorigenesis through constitutive activation of downstream signaling pathways (e.g., PI3K/AKT, RAS/RAF/MEK), viral infections may modulate these same pathways, potentially enhancing tumor aggressiveness or altering therapeutic response [26, 40]. This evidence concerns the gene MAP2K7 and viral infectious disease.